Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 220-585-8 | CAS number: 2825-82-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Toxicity to reproduction
Administrative data
- Endpoint:
- screening for reproductive / developmental toxicity
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- the study does not need to be conducted because a pre-natal developmental toxicity study is available
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- data waiving: supporting information
Reference
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Not reported.
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with national standard methods with acceptable restrictions
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- - Principle of test:
Evaluation of the effect of the test material on the development of embryonic rats.
- Short description of test conditions: Mated female rats received test material by gavage at the dose levels of 0, 250, 500, or 1000 mg/kg bw/day on days 6 through 15 of gestation. The test material was diluted with corn oil and controls received an equivalent volume of corn oil (2.0 ml/kg bw/day).
- Parameters analysed / observed: All animals were weighed and observed daily for clinical signs. The animals were sacrificed at gestational day 20 (gd20) and the fetuses were delivered by caesarean section. The number and placement of fetuses and resorption sites were recorded. Fetuses were removed, weighed, sexed, and examined for external, soft tissue and skeletal abnormalities. - GLP compliance:
- no
- Remarks:
- Pre-GLP
- Limit test:
- no
- Species:
- rat
- Strain:
- Fischer 344
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Breeding Laboratories
- Age at study initiation: not reported
- Weight at study initiation: approx. 172, 175, 173 and 174 g for groups exposed to 0, 250, 500 and 1000 mg/kg bw/d, respectively.
- Fasting period before study: not reported
- Housing: plastic cages containing wood chip bedding
- Diet (e.g. ad libitum): Ralston Purina Co. ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: not reported
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 72-76 °F
- Humidity (%): not reported
- Air changes (per hr): not reported
- Photoperiod (hrs dark / hrs light): 12h / 12h
IN-LIFE DATES: not reported - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
VEHICLE
- Justification for use and choice of vehicle (if other than water): not reported
- Concentration in vehicle: not reported
- Amount of vehicle (if gavage): Total volume: 2 mL/kg bw/d
- Lot/batch no. (if required): not reported
- Purity: not reported - Analytical verification of doses or concentrations:
- not specified
- Details on mating procedure:
- - Impregnation procedure: cohoused
- If cohoused: The females were placed with fertile males of the same stock overnight and checked for presence of sperm by vaginal wash the next morning.
- Proof of pregnancy: The day on which sperm was found was designated day 0 of pregnancy. - Duration of treatment / exposure:
- by gavage on days 6 through 15 of gestation.
- Frequency of treatment:
- daily from gd 6 to gd15
- Duration of test:
- until gd 20
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Remarks:
- Group 1 (Control)
- Dose / conc.:
- 250 mg/kg bw/day (nominal)
- Remarks:
- Group 2 (Low dose)
- Dose / conc.:
- 500 mg/kg bw/day (nominal)
- Remarks:
- Group 2 (Mid dose)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- Remarks:
- Group 4 (High dose)
- No. of animals per sex per dose:
- Not reported
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- No data
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: No data
DETAILED CLINICAL OBSERVATIONS: No data
BODY WEIGHT: Yes
- Time schedule for examinations: daily
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day #20
- Organs examined: No data - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: No data
- Number of implantations: Yes
- Number of resorptions: Yes - Fetal examinations:
- - External examinations: Yes: all per litter
- Soft tissue examinations: Yes: half per litter
- Skeletal examinations: Yes: half per litter
- Head examinations: No data - Statistics:
- Measured data were analyzed for statistical significance by the Student's t method and are listed as mean +/- standard deviation (S.D.).
Incidence data were analyzed with Fisher's exact test.
The level of significance chosen for all tests was p < 0.05. - Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Many animals in the 1000 mg/kg bw/d group exhibited tremors and a few also had mild convulsions.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Treated rats gained less weight than the controls during the treatment period.
The decreased weight gain was dose related with both the 1000 mg/kg and 500 mg/kg orally dosed groups.
The 1000 mg/kg bw/d group also gained significantly less weight during the latter phase of treatment.
The values for total weight gained during gestation and also maternal weight gain (gd20 weight with gravid uterus removed - gd0 weight) were also significantly reduced in the 1000 mg/kg bw/d group.
The weight gain following cessation of treatment was not signficantly different from the control for any group. - Early or late resorptions:
- effects observed, treatment-related
- Description (incidence and severity):
- There was a statistically significant increase in litters containing resorptions amounting to 25 percent or more of the implants in the high dose group; however, the incidence of resorptions / litter although elevated was not significant.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 500 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: tremors and mild convulsions at 1000 mg/kg bw/day
- Fetal body weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The 500 mg/kg bw/d dosed group had a significantly reduced fetal weight while the 1000 mg/kg bw/d group did not.
- Reduction in number of live offspring:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were an increase in embryolethality in the 1000 mg/kg bw/d group but this is probably due to a maternal toxicity (secondary effect).
- External malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The incidence of malformation was not significantly elevated for any treatment group.
The most common major malformation observed in the 2 higher dosed groups was nanoidism. This abnormality did not occur in the control or lowest dose group in this study but has occured in other control litters historically in this laboratory at a rate similar to that observed in the higher treatment group. - Visceral malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The second most common major malformation involved the urinary tract development. The malformation included hydro-nephrosis, dilated ureter, and agenesis of the bladder. It occured in 3 fetuses from 1 litter. Since the substance was observed in the fetuses from only one litter it probably arose spontaneously rather than as a result of the test material treatment. Thus, the incidence of this major malformations at the higher dose does not appear significant.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- not specified
- Basis for effect level:
- other: effects are due to maternal toxicity at 1000 mg/kg bw/day (increase in embryolethality) and at 500 mg/kg bw/day (decrease in fetal weight)
- Key result
- Developmental effects observed:
- no
- Conclusions:
- Under the test conditions, the NOAEL for maternal toxicity is 500 mg/kg bw/day and the NOAEL for developmental toxicity is 1000 mg/kg bw/day in rats.
- Executive summary:
In a pre-natal developmental toxicity study, test substance was administered by oral route (gavage) to groups of mated female rats at the dose levels of 0, 250, 500, or 1000 mg/kg bw/day on days 6 through 15 of gestation. The test material was diluted with corn oil and controls received an equivalent volume of corn oil (2.0 ml/kg bw/day). All animals were weighed and observed daily for clinical signs. The animals were sacrificed at gestational day 20 (gd20) and the fetuses were delivered by caesarean section.
The number and placement of fetuses and resorption sites were recorded. Fetuses were removed, weighed, sexed, and examined for external, soft tissue and skeletal abnormalities.
There was a decreased weight gain in the two higher dose groups and tremors and mild convulsions were observed in the top dose group.
Data concerning nonteratogenic embryotoxicity were ambigous.
There were an increase in embryolethality in the 1000 mg/kg bw/d group and a decrease in fetal weight in the 500 mg/kg bw/d group. These indicators of embryotoxicity were not distributed in a dose-related manner. Most likely they were secondary to maternal toxicity (reduced weight gains, tremors, and convulsions) in the high dosed groups.
Under the test conditions, the NOAEL for maternal toxicity is 500 mg/kg bw/day and the NOAEL for developmental toxicity is 1000 mg/kg bw/day in rats.
- Reason / purpose for cross-reference:
- data waiving: supporting information
Reference
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Not reported.
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with national standard methods with acceptable restrictions
- Reason / purpose for cross-reference:
- reference to other study
- Reason / purpose for cross-reference:
- reference to other study
- Reason / purpose for cross-reference:
- reference to other study
- Principles of method if other than guideline:
- - Principle of test:
Evaluation of the teratogenic effects of the test substance on the ICR mice.
- Short description of test conditions: mated female mice were treated by gavage with test substance at the dose levels of 0, 0.2, 0.4, 0.6 or 0.8 mL/kg bw/day, which corresponds to 0, 187, 374, 561 or 748 mg/kg bw/day, on days 6 through 9 of gestation. The test material was diluted with soybean or mineral oil and controls received soybean or mineral oil.
- Parameters analysed / observed: All animals were weighed and observed daily for clinical signs. The animals were sacrificed at gestational day 17 (gd17) and the fetuses were delivered by caesarean section. The number and position of each fetus was recorded, weighed and examined for external, soft tissues and skeletal abnormalities. - GLP compliance:
- no
- Remarks:
- Pre-GLP
- Limit test:
- no
- Species:
- mouse
- Strain:
- ICR
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Industries
- Age at study initiation: not reported
- Weight at study initiation: not reported
- Fasting period before study: not reported
- Housing: plastic cages containing wood chip bedding
- Diet (e.g. ad libitum): Purina Mouse Chow ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: not reported
ENVIRONMENTAL CONDITIONS
- Temperature: 70-76 °F
- Humidity (%): not reported
- Air changes (per hr): not reported
- Photoperiod (hrs dark / hrs light): 12h / 12h
IN-LIFE DATES: From: To: not reported - Route of administration:
- oral: gavage
- Vehicle:
- other: soybean or mineral oil
- Details on exposure:
- None reported
- Analytical verification of doses or concentrations:
- not specified
- Details on mating procedure:
- - Impregnation procedure: cohoused
- If cohoused: Four to five females were kept with each male. The females were checked for presence of a vaginal plug early in the morning and again late in the afternoon.
- Proof of pregnancy: The day that a vaginal plug was found was designated day 0 of pregnancy and the females were moved to wire bottomed cages. - Duration of treatment / exposure:
- by gavage on days 6 through 9 of gestation
- Frequency of treatment:
- daily
- Duration of test:
- until gd17
- Dose / conc.:
- 0 other: mL/kg bw/day
- Remarks:
- Group 1 (Control)
- Dose / conc.:
- 0.2 other: mL/kg bw/day
- Remarks:
- Group 2 (Low dose, ca. 187 mg/kg bw/day)
- Dose / conc.:
- 0.4 other: mL/kg bw/day
- Remarks:
- Group 3 (Mid dose, ca. 374 mg/kg bw/day)
- Dose / conc.:
- 0.6 other: mL/kg bw/day
- Remarks:
- Group 4 (High dose, ca. 561 mg/kg bw/day)
- Dose / conc.:
- 0.8 other: mL/kg bw/day
- Remarks:
- Group 5 (High dose, ca. 748 mg/kg bw/day)
- No. of animals per sex per dose:
- Not reported
- Control animals:
- yes, concurrent vehicle
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: No data
DETAILED CLINICAL OBSERVATIONS: No data
BODY WEIGHT: Yes
- Time schedule for examinations: daily
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day #17
- Organs examined: No data - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: No data
- Number of implantations: Yes
- Number of resorptions: Yes - Fetal examinations:
- - External examinations: Yes: all per litter
- Soft tissue examinations: Yes: two thirds per litter
- Skeletal examinations: Yes: one third per litter
- Head examinations: No data - Statistics:
- Measured data were analyzed for statistical significance by the Student's t method and are listed as mean +/- standard deviation (S.D.).
Incidence data were analyzed with Fisher's exact test.
The level of significance chosen for all tests was p = 0.05. - Clinical signs:
- no effects observed
- Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The increased maternal weight in the 0.2 and 0.4 ml/kg bw/d groups is apparently due to increased fetal weight and the increased maternal weight gain in the 0.8 ml/kg bw/d group is due to slightly larger average litter size.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 0.8 other: mL/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- other: no adverse effects observed
- Remarks on result:
- other: ca. 748 mg/kg bw/day
- Fetal body weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There was a difference found in mean fetal weights. At doses of 0.2 and 0.4 ml/kg w/d the mean fetal weight was significantly heavier (p=0.05) than in the controls and there was a corresponding higher mean weight gain in the females in these treatment groups and in the 0.8 ml/kg bw/d group.
The increased fetal weight is not easily explained particularly when no such increase occurred in the groups receiving 0.6 and 0.8 ml/kg bw/d. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 0.8 other: mL/kg bw/day
- Based on:
- test mat.
- Sex:
- not specified
- Basis for effect level:
- other: no adverse effects observed
- Remarks on result:
- other: ca. 748 mg/kg bw/day
- Key result
- Developmental effects observed:
- no
- Conclusions:
- Under the test conditions, the test substance is not embryotoxic up to 0.8 mL/kg bw/d (ca. 748 mg/kg bw/d).
- Executive summary:
In a pre-natal developmental toxicity study, test substance was administered by oral route (gavage) to groups of mated female mice at the dose levels of 0, 0.2, 0.4, 0.6 or 0.8 mL/kg bw/day which corresponds to 0, 187, 374, 561 or 748 mg/kg bw/day on days 6 through 9 of gestation. The test material was diluted with soybean or mineral oil and controls received soybean or mineral oil. All animals were weighed and observed daily for clinical signs. The animals were sacrificed at gestational day 17 (gd17) and the fetuses were delivered by caesarean section. The number and position of each fetus was recorded, weighed and examined for external, soft tissues and skeletal abnormalities.
The following comparisons were made between the control and experimental groups: mean implants/female, mean viable fetuses/litter, mean resorptions/litter, frequency of resorptions, frequency of soft tissue anomaly, and frequency of skeletal anomaly.
In ICR mice the test substance does not cause an increase in fetal malformations. The same result was found by Keller et al. (1981), after exposing Fisher 344 rats to oral doses of 250, 500 and 1000 mg/kg/d and an inhalation dose of 572 ppm for six hours per day (nominal dose of 600 ppm). All groups were exposed on day 6 through 15 of gestation. They did find that rats receiving 1000 mg/kg and the inhalation dose showed tremors and moderate convulsions and a reduction in maternal weight gain. These effects were not observed in mice. Mice are more sensitive to the toxic effects of test substance having a LD50 of 3.9 ml/kg while the LD50 in rats is over 20 ml/kg bw (Kinkead 1979). The concentrations used in the mouse study were higher in proportion to the toxic dose than those in the rat study. Even so there was no increase in the incidence of fetal malformations.
The increased fetal weight in the mouse study is not easily explained particularly when no such increase occurred in the groups receiving 0.6 and 0.8 ml/kg bw/d. The increased maternal weight in the 0.2 and 0.4 ml/kg bw/d groups is apparently due to increased fetal weight and the increased maternal weight gain in the 0.8 ml/kg bw/d group is due to slightly larger average litter size.
Under this test conditions, the NOAEL for maternal and developmental toxicity is 0.8 mL/kg bw/day in mice which corresponds to 748 mg/kg bw/day.
Data source
Materials and methods
Results and discussion
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)